Key Takeaways:
Legend Biotech reached its first quarter of company-wide profitability in Q2 2026, with adjusted net income of $63.1 million and revenue of $387.5 million up 52% year over year, as CARVYKTI sales accelerated across earlier treatment lines.
"This is a leadership transition, not a strategy transition," Interim Chief Executive Officer Alan Bash said. "Our priorities remain unchanged. We remain focused on three main objectives: maximizing CARVYKTI, advancing our next generation pipeline, and strengthening our execution on all fronts."
CARVYKTI, the BCMA-directed CAR-T therapy Legend co-develops with Johnson & Johnson through its Janssen unit, delivered worldwide net trade sales of $657 million, up 50% year over year. U.S. sales rose 32%, while ex-U.S. sales jumped 128% as the therapy expanded to 19 markets and 348 activated treatment sites. Adjusted earnings of $0.16 per share beat the $0.07 consensus by 128.57%, while revenue topped the $362.81 million estimate by 6.81%.
The profitability milestone marks a shift from development-stage biotech to commercial enterprise. Operating margin improved to positive 15% from negative 9% a year earlier and negative 142% in Q2 2023, while revenue has compounded at 74% annually since then. Shares rose 5.03% premarket to $21.70, though they remain well below the 52-week high of $38.35.
The growth reflects accelerating adoption of CARVYKTI in second through fourth lines of treatment, which now account for more than 70% of U.S. volume. Management said earlier-line use is the fastest-growing part of the business, with more than 150 authorized U.S. treatment centers, roughly 40% of which are community hospitals. Gross margin on net product sales improved to 58% from 41% in Q1 2026, though management expects it to dip to the lower 50% range in Q3 before rebounding to the mid-50% range in Q4.
Total operating expenses rose just 7% year over year to $192.4 million, well below the 52% revenue growth rate. Research and development spending fell 2% to $96.0 million as later-stage BCMA frontline study costs rolled off, while selling, general and administrative expenses rose 19% to $96.4 million to support CARVYKTI's market position.
Beyond CARVYKTI, Legend presented first clinical proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed or refractory B-cell non-Hodgkin lymphoma. At the higher dose level, the therapy achieved a 100% overall response rate and an 83.3% complete response rate across six patients, with CAR-T cells detectable in peripheral blood for up to 116 days. The company plans to file a U.S. investigational new drug application by year-end and run the initial Phase 1 study internally.
The in vivo platform, which uses a lentiviral vector approach distinct from Sail's circular mRNA and lipid nanoparticle platform, is central to Legend's long-term strategy. The company is advancing 14 pipeline programs across autologous, allogeneic, and in vivo CAR-T therapies, including LB2102, a DLL3-targeted candidate for small cell lung cancer licensed to Novartis, which showed a 28.6% objective response rate at higher dose levels.
Legend ended the quarter with approximately $965 million in cash, cash equivalents, and time deposits and no long-term debt, boosted by about $212 million in net proceeds from a June public offering. Chief Financial Officer Carlos Santos said the raise provides flexibility to accelerate LB2501 development and the broader in vivo platform. The company expects to fully settle a roughly $300 million loan to Johnson & Johnson in 2026.
Management maintained its outlook for sequential global revenue growth in Q3 and Q4, adjusted net income profitability through the second half, and a Q4 IND filing for LB2501. The company expects a tax rate in the high 20% range over the next several quarters.
Legend shares, trading at $21.88 midday, remain well below the consensus analyst target of $52.10, with price targets ranging from $27 to $80. The profitability milestone and in vivo data could support further re-rating, though the company faces margin volatility as outpatient use approaches 60% of volume, an ongoing CEO search, and competition from bispecific therapies and Bristol Myers Squibb's Abecma in later-line multiple myeloma.
This article is for informational purposes only and does not constitute investment advice.
